Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

A Novel Prognostic Index for Ocular Adnexal Lymphoma

Marshall W. Meeks, BS, Henry S. Park, MD MPH, James B. Yu, MD MHS, Kenneth B. Roberts, MD, Francine Foss, MD, Lynn D. Wilson, MD MPH

Blood (2016) 128 (22): 3597.

https://doi.org/10.1182/blood.V128.22.3597.3597

Published: 2016

Journal Articles

First Multicenter, Randomized Phase 3 Study in Patients (Pts) with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (Lumiere trial; NCT01482962)

Blood (2015) 126 (23): 341.

https://doi.org/10.1182/blood.V126.23.341.341

Published: 2015

Journal Articles

Correlation of Target Molecule Expression and Overall Response in Refractory Cutaneous T-Cell Lymphoma Patients Dosed with Mogamulizumab (KW-0761), a Monoclonal Antibody Directed Against CC Chemokine Receptor Type 4 (CCR4)

Madeleine Duvic, MD, Lauren Pinter-Brown, Francine Foss, MD, Lubomir Sokol, MD, PhD, Jeffrey Jorgensen, MD, PhD, Xiao Ni, MD, PhD, Pramoda Challagundla, MS, Meghali Goswami, BS, Karen Dwyer, Nehal Mohamed, PhD, Youn H Kim, MD

Blood (2012) 120 (21): 3697.

https://doi.org/10.1182/blood.V120.21.3697.3697

Published: 2012

Journal Articles

Complete Responses with Denileukin Diftitox in Cutaneous T-Cell Lymphoma Studies.

Francine Foss, MD, Madeleine Duvic, MD, Elise A. Olsen, MD, Anna Kozlovski, Pharm, D

Blood (2009) 114 (22): 3745.

https://doi.org/10.1182/blood.V114.22.3745.3745

Published: 2009

Journal Articles

Stem Cell Mobilization Using 5 Pm Dosing of Plerixafor.

Dennis L Cooper, MD, Julie Baker, APRN, Erin Medoff, APRN, Kathryn Pratt, RN, Ann Conkling-Walsh, RN, Edward L. Snyder, MD, Stuart Seropian, MD, Francine Foss, MD

Blood (2009) 114 (22): 4233.

https://doi.org/10.1182/blood.V114.22.4233.4233

Published: 2009

Journal Articles

Should All Patients with Acute Myelogenous Leukemia (AML) Other Than Good Risk Cytogenetics Receive Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in First Remission?

Onder Alpdogan, MD, Raymond Lenox, APRN, Amy Barile, APRN, Francine Foss, MD, Warren Shlomchik, MD, Christy Reuben, APRN, Dennis Cooper, MD, Stuart Seropian, MD

Blood (2008) 112 (11): 4396.

https://doi.org/10.1182/blood.V112.11.4396.4396

Published: 2008

Journal Articles

Outcomes in Subcutaneous Panniculitis-Like T-Cell Lymphoma (STCL)

Onder Alpdogan, MD, Deborah Ornstein, MD, Tony Subtil, MD, Stuart Seropian, MD, Dennis L. Cooper, MD, Francine Foss, MD

Blood (2008) 112 (11): 3750.

https://doi.org/10.1182/blood.V112.11.3750.3750

Published: 2008

Journal Articles

Efficacy of Extracorporeal Photopheresis (ECP) Monotherapy in the Treatment of Cutaneous T Cell Lymphoma.

Larisa Geskin, MD, FAAD, Francine Foss, MD, Madeleine Duvic, MD, David Straus, MD, Steven Horwitz, MD, Jasmine Zain, MD, Timothy Kuzel, MD, Christiane Querfeld, MD, Kim Campbell, PhD, Robert Knobler, MD

Blood (2007) 110 (11): 2561.

https://doi.org/10.1182/blood.V110.11.2561.2561

Published: 2007

Journal Articles

Response to Oral Forodesine in Refractory Cutaneous T-Cell Lymphoma: Interim Results of a Phase I/II Study.

Madeleine Duvic, MD, Andres Forero-Torres, MD, Francine Foss, MD, Elise Olsen, MD, Youn Kim, MD

Blood (2007) 110 (11): 122.

https://doi.org/10.1182/blood.V110.11.122.122

Published: 2007

Journal Articles

Denileukin Diftitox (ONTAK) Plus CHOP Chemotherapy in Patients with Peripheral T-Cell Lymphomas (PTCL), the CONCEPT Trial.

Francine Foss, MD, Nelida Sjak-Shie, MD, PhD, Andre Goy, MD, Eric Jacobsen, MD, Ranjana Advani, MD, Mitchell Smith, MD, PhD, Rami Komrokji, MD, Kelly Pendergrass, MD, Vanessa Bolejack, MPH, Karen Watts, Mark Acosta, PharmD

Blood (2007) 110 (11): 3449.

https://doi.org/10.1182/blood.V110.11.3449.3449

Published: 2007

Journal Articles

Efficacy and Safety of Denileukin Diftitox (Ontak®) in the Treatment of Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status.

Francine Foss, MD, Madeleine Duvic, MD, Larisa Geskin, MD, Joseph Anderson, MD, Pierluigi Porcu, MD, Raymond J. Hohl, MD,PhD, Maureen Cooper, MD, Jasmine M. Zain, MD, John Zic, MD, Patrica Hibberd, MD,PhD, Mark Acosta, PharmD

Blood (2006) 108 (11): 2712.

https://doi.org/10.1182/blood.V108.11.2712.2712

Published: 2006

Journal Articles

SGN-30 (Anti-CD30 mAb) Has a Single-Agent Response Rate of 21% in Patients with Refractory or Recurrent Systemic Anaplastic Large Cell Lymphoma (ALCL).

Blood (2006) 108 (11): 2718.

https://doi.org/10.1182/blood.V108.11.2718.2718

Published: 2006

Journal Articles

A Phase I Open Label Dose Escalation Study To Evaluate MEDI-507 in Patients with CD2-Positive T-Cell Lymphoma/Leukemia.

Deborah A. Casale, MS, Nancy L. Bartlett, MD, David D. Hurd, MD, Francine Foss, MD, Barbara Pro, MD, Lubomir Sokol, MD, PhD, Ronald Lieberman, MD, Hammershaimb Luz, MD

Blood (2006) 108 (11): 2727.

https://doi.org/10.1182/blood.V108.11.2727.2727

Published: 2006

Journal Articles

FDG-PET Scans as a Staging Study for T-Cell Lymphomas: High Rates of Positivity Do Not Result in Frequent Changes in Stage.

Steven M. Horwitz, MD, Francine Foss, MD, Shari Goldfarb, MD, Ana Molina, MD, Paul A. Hamlin, MD, Owen A. O’Connor, MD, PHD, Michelle Cammarata, Craig H. Moskowitz, MD, Andrew D. Zelenetz, MD, PHD

Blood (2006) 108 (11): 2399.

https://doi.org/10.1182/blood.V108.11.2399.2399

Published: 2006

Journal Articles

Oral Forodesine (Bcx-1777) Is Clinically Active in Refractory Cutaneous T-Cell Lymphoma: Results of a Phase I/II Study.

Madeleine Duvic, MD, Andres Forero-Torres, MD, Francine Foss, MD, Elsie A. Olsen, MD, Youn Kim, MD

Blood (2006) 108 (11): 2467.

https://doi.org/10.1182/blood.V108.11.2467.2467

Published: 2006

Journal Articles

SGN-30 (Anti-CD30 Monoclonal Antibody) Is Active and Well Tolerated in Patients with Refractory or Recurrent Systemic Anaplastic Large Cell Lymphoma (ALCL).

Andres Forero-Torres, MD, Steven H. Bernstein, MD, Ajay K. Gopal, MD, Francine Foss, MD, John P. Leonard, MD, Joseph D. Rosenblatt, MD, Nancy L. Bartlett, MD, Bruce D. Cheson, MD, Elliott Epner, MD, Francisco J. Hernandez-Illizaliturri, MD, Stephen J. Proctor, MD, Pauline Brice, MD, Harve Tilly, MD, Corinne Haioun, MD, Mats Jerkeman, MD, Andre Bosly, MD, Jennie M. Lorenz, Jeremy Barton, MD

Blood (2005) 106 (11): 3356.

https://doi.org/10.1182/blood.V106.11.3356.3356

Published: 2005

Journal Articles

Preliminary Phase II Results of SGN-30 (Anti-CD30 Monoclonal Antibody) in Patients with Cutaneous Anaplastic Large Cell Lymphoma (ALCL).

Madeleine Duvic, MD, Joy Kunishige, MD, Youn H. Kim, MD, Andres Foreno-Torres, MD, Lauren C. Pinter-Brown, MD, Mark U. Rarick, MD, John Zic, MD, Sophie M. Worobec, MD, Francine Foss, MD, Karen Flessland, Jeremy Barton, MD

Blood (2005) 106 (11): 4802.

https://doi.org/10.1182/blood.V106.11.4802.4802

Published: 2005

Journal Articles

Response to Tositumomab and Iodine 131 I-Tositumomab (BEXXAR) Based on International Prognostic Index (IPI) Score.

Sridhar E. Pal, MD, Eric S. Winer, MD, Kevin Chin, MD, Alisa Dungy, Beth Higgins, Francine Foss, MD.

Blood (2004) 104 (11): 4630.

https://doi.org/10.1182/blood.V104.11.4630.4630

Published: 2004

Journal Articles

Cytomegalovirus Reactivation and Relapse Following Allogeneic Stem Cell Transplantation Using a Reduced Intensity Conditioning Regimen.

Revati Rao, MD, Kevin Chin, MD, Geoff Chan, MD, Kellie Sprague, MD, Andreas Klein, MD, Kenneth B. Miller, MD, Francine Foss, MD, David R. Snydman, MD

Blood (2004) 104 (11): 5104.

https://doi.org/10.1182/blood.V104.11.5104.5104

Published: 2004

Journal Articles

Potential TH9402-Based ECP Treatment for cGvHD Patients.

Annie Levesque, M.Sc, Ann-Louise Savard, Denis-Claude Roy, MD, Francine Foss, MD, Christian Scotto, Ph.D

Blood (2004) 104 (11): 5119.

https://doi.org/10.1182/blood.V104.11.5119.5119

Published: 2004

NARROW

A Novel Prognostic Index for Ocular Adnexal Lymphoma

First Multicenter, Randomized Phase 3 Study in Patients (Pts) with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (Lumiere trial; NCT01482962)

Correlation of Target Molecule Expression and Overall Response in Refractory Cutaneous T-Cell Lymphoma Patients Dosed with Mogamulizumab (KW-0761), a Monoclonal Antibody Directed Against CC Chemokine Receptor Type 4 (CCR4)

Complete Responses with Denileukin Diftitox in Cutaneous T-Cell Lymphoma Studies.

Stem Cell Mobilization Using 5 Pm Dosing of Plerixafor.

Should All Patients with Acute Myelogenous Leukemia (AML) Other Than Good Risk Cytogenetics Receive Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in First Remission?

Outcomes in Subcutaneous Panniculitis-Like T-Cell Lymphoma (STCL)

Efficacy of Extracorporeal Photopheresis (ECP) Monotherapy in the Treatment of Cutaneous T Cell Lymphoma.

Response to Oral Forodesine in Refractory Cutaneous T-Cell Lymphoma: Interim Results of a Phase I/II Study.

Denileukin Diftitox (ONTAK) Plus CHOP Chemotherapy in Patients with Peripheral T-Cell Lymphomas (PTCL), the CONCEPT Trial.

Efficacy and Safety of Denileukin Diftitox (Ontak®) in the Treatment of Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status.

SGN-30 (Anti-CD30 mAb) Has a Single-Agent Response Rate of 21% in Patients with Refractory or Recurrent Systemic Anaplastic Large Cell Lymphoma (ALCL).

A Phase I Open Label Dose Escalation Study To Evaluate MEDI-507 in Patients with CD2-Positive T-Cell Lymphoma/Leukemia.

FDG-PET Scans as a Staging Study for T-Cell Lymphomas: High Rates of Positivity Do Not Result in Frequent Changes in Stage.

Oral Forodesine (Bcx-1777) Is Clinically Active in Refractory Cutaneous T-Cell Lymphoma: Results of a Phase I/II Study.

SGN-30 (Anti-CD30 Monoclonal Antibody) Is Active and Well Tolerated in Patients with Refractory or Recurrent Systemic Anaplastic Large Cell Lymphoma (ALCL).

Preliminary Phase II Results of SGN-30 (Anti-CD30 Monoclonal Antibody) in Patients with Cutaneous Anaplastic Large Cell Lymphoma (ALCL).

Response to Tositumomab and Iodine 131 I-Tositumomab (BEXXAR) Based on International Prognostic Index (IPI) Score.

Cytomegalovirus Reactivation and Relapse Following Allogeneic Stem Cell Transplantation Using a Reduced Intensity Conditioning Regimen.

Potential TH9402-Based ECP Treatment for cGvHD Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only